4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 542.00
-20.50 (-3.64%)
Oct 15, 2026, 2:04 PM GMT
4basebio Revenue
4basebio had revenue of 262.00K GBP in the half year ending June 30, 2026, a decrease of -20.12%. This brings the company's revenue in the last twelve months to 781.00K, down -56.10% year-over-year. In the year 2025, 4basebio had annual revenue of 1.69M with 81.46% growth. That makes 4basebio the 43,529th largest company in the world by revenue and 871st in the United Kingdom.
Revenue (ttm)
781.00K
Revenue Growth
-56.10%
P/S Ratio
111.91
Revenue / Employee
5.58K
Employees
140
Market Cap
84.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.69M | 760.00K | 81.46% |
| Dec 31, 2024 | 933.00K | 427.00K | 84.39% |
| Dec 31, 2023 | 506.00K | 238.00K | 88.81% |
| Dec 31, 2022 | 268.00K | -70.00K | -20.71% |
| Dec 31, 2021 | 338.00K | -124.00K | -26.84% |
| Dec 31, 2020 | 462.00K | 260.00K | 128.71% |
| Dec 31, 2019 | 202.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.54M |
| PureTech Health | 4.80M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| Arecor Therapeutics | 890.00K |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
4basebio News
- 7 hours ago - 4basebio Plc - Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million - Finanz Nachrichten
- 5 weeks ago - 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine - Finanz Nachrichten
- 7 weeks ago - 4basebio & Genezen Expand Collaboration For Viral Vector Manufacturing; Stock Up - Nasdaq
- 7 weeks ago - 4basebio Plc - 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing - Finanz Nachrichten
- 2 months ago - 4basebio Plc - Grant of Options & Director/PDMR Dealing - Finanz Nachrichten
- 3 months ago - 4basebio Plc - Director Appointment - Finanz Nachrichten
- 3 months ago - 4basebio Plc - Result of AGM & Issue of Options - Finanz Nachrichten
- 4 months ago - 4basebio Plc - Notice of Investor Presentation - Finanz Nachrichten